These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 30927241)

  • 21. Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.
    Gæde P; Johansen P; Tikkanen CK; Pollock RF; Hunt B; Malkin SJP
    Diabetes Ther; 2019 Aug; 10(4):1297-1317. PubMed ID: 31098942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Utility Analysis of Once-Weekly Semaglutide, Dulaglutide, and Exenatide for Type 2 Diabetes Patients Receiving Metformin-Based Background Therapy in China.
    Hu S; Wang S; Qi C; Gu S; Shi C; Mao L; Fan G
    Front Pharmacol; 2022; 13():831364. PubMed ID: 35250578
    [No Abstract]   [Full Text] [Related]  

  • 23. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
    Gorgojo-Martínez JJ; Malkin SJP; Martín V; Hallén N; Hunt B
    J Med Econ; 2020 Feb; 23(2):193-203. PubMed ID: 31613199
    [No Abstract]   [Full Text] [Related]  

  • 24. Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model.
    Yuan S; Wu Y
    Front Public Health; 2023; 11():1201818. PubMed ID: 37744474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain.
    Vidal J; Malkin SJP; Hunt B; Martín V; Hallén N; Javier Ortega F
    Diabetes Ther; 2020 Feb; 11(2):509-521. PubMed ID: 31925724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China.
    Liu L; Ruan Z; Ung COL; Zhang Y; Shen Y; Han S; Jia R; Qiao J; Hu H; Guo L
    Diabetes Ther; 2023 Jan; 14(1):93-107. PubMed ID: 36414806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China.
    Feng Z; Tong WK; Zhang X; Tang Z
    Front Pharmacol; 2023; 14():1226778. PubMed ID: 37621313
    [No Abstract]   [Full Text] [Related]  

  • 28. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
    Johansen P; Chubb B; Hunt B; Malkin SJP; Sandberg A; Capehorn M
    Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting.
    Capehorn M; Hallén N; Baker-Knight J; Glah D; Hunt B
    Diabetes Ther; 2021 Feb; 12(2):537-555. PubMed ID: 33423240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
    Pratley RE; Aroda VR; Lingvay I; Lüdemann J; Andreassen C; Navarria A; Viljoen A;
    Lancet Diabetes Endocrinol; 2018 Apr; 6(4):275-286. PubMed ID: 29397376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark.
    Ehlers LH; Lamotte M; Ramos MC; Sandgaard S; Holmgaard P; Kristensen MM; Ejskjaer N
    Diabetes Ther; 2022 Mar; 13(3):489-503. PubMed ID: 35187628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥30 kg/m
    Dilla T; Alexiou D; Chatzitheofilou I; Ayyub R; Lowin J; Norrbacka K
    J Med Econ; 2017 May; 20(5):443-452. PubMed ID: 28008768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression.
    Lingvay I; Bauer R; Baker-Knight J; Lawson J; Pratley R
    J Clin Endocrinol Metab; 2022 Apr; 107(5):1461-1469. PubMed ID: 34922383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
    Chuang LH; Verheggen BG; Charokopou M; Gibson D; Grandy S; Kartman B
    J Med Econ; 2016 Dec; 19(12):1127-1134. PubMed ID: 27310712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.
    Yabe D; Nakamura J; Kaneto H; Deenadayalan S; Navarria A; Gislum M; Inagaki N;
    Lancet Diabetes Endocrinol; 2020 May; 8(5):392-406. PubMed ID: 32333876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11.
    Evans M; Chubb B; Malkin SJP; Berry S; Lawson J; Hunt B
    Diabetes Obes Metab; 2023 Feb; 25(2):491-500. PubMed ID: 36251282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study.
    Pulleyblank R; Larsen NB
    Pharmacoecon Open; 2023 Jul; 7(4):579-591. PubMed ID: 37178435
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
    Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
    J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
    [No Abstract]   [Full Text] [Related]  

  • 39. A model-based simulation of glycaemic control and body weight when switching from semaglutide to 3.0- and 4.5-mg doses of once-weekly dulaglutide.
    Tham LS; Pantalone KM; Dungan K; Munir K; Tang CC; Konig M; Kwan AYM
    Diabetes Obes Metab; 2022 Feb; 24(2):302-311. PubMed ID: 34697882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus.
    Capel M; Ciudin A; Mareque M; Rodríguez-Rincón RM; Simón S; Oyagüez I
    Pharmacoecon Open; 2020 Jun; 4(2):277-286. PubMed ID: 31338828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.